|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2005-5-30
|
|
pubmed:abstractText |
Gastroesophageal reflux disease (GERD), which is reflux that produces damage or troubling symptoms, afflicts approximately 7% of infants and children to the extent that administration of physician-directed pharmacotherapy is warranted.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0149-2918
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
472-83
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15922820-Adolescent,
pubmed-meshheading:15922820-Adult,
pubmed-meshheading:15922820-Capsules,
pubmed-meshheading:15922820-Chemistry, Pharmaceutical,
pubmed-meshheading:15922820-Child,
pubmed-meshheading:15922820-Child, Preschool,
pubmed-meshheading:15922820-Drug Administration Schedule,
pubmed-meshheading:15922820-Drug Tolerance,
pubmed-meshheading:15922820-Female,
pubmed-meshheading:15922820-Gastroesophageal Reflux,
pubmed-meshheading:15922820-Histamine H2 Antagonists,
pubmed-meshheading:15922820-Humans,
pubmed-meshheading:15922820-Infant,
pubmed-meshheading:15922820-Infant, Newborn,
pubmed-meshheading:15922820-Male,
pubmed-meshheading:15922820-Nizatidine,
pubmed-meshheading:15922820-Solutions
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
|
|
pubmed:affiliation |
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15238, USA. sro1205@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
